Skip to main content
SpringerLink
Log in

Low Molecular Weight Heparins in the Cardiac Catheterization Laboratory

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gurfinkel EP, Manos EJ, Mejaíl RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313–318.

    Google Scholar 

  2. Wallentin L. for the Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecularweight heparin during instability in coronary artery disease. Lancet 1996;347:561–568.

    Google Scholar 

  3. Klein W, Buchwald A, Hillis SE, et al. (FRIC) Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 1997;96: 61–68.

    Google Scholar 

  4. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337:447–452.

    Google Scholar 

  5. Leizorowicz A. FRAXIS: Fraxiparine in ischemic syndromes. Presentation at the European Society of Cardiology, Vienna, August, 1998.

  6. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty: Results of the Enoxaparin Restenosis (ERA) Trial. Circulation 1994;90:908–914.

    Google Scholar 

  7. Brack MJ, Ray S, Chauhan A, et al. The subcutaneous heparin and angioplasty restenosis prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome. J Am Coll Cardiol 1995;26:947–954.

    Google Scholar 

  8. Cairns JA, Gill J, Morton B, et al. Fish oils and low molecular weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR study. Circulation 1996;94:1553–1560.

    Google Scholar 

  9. Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (Reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double blind, unfractioned heparin and placebo controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996;28: 1437–1443.

    Google Scholar 

  10. Lablanche JM, McFadden EP, Meneveau N, et al. Effect of nadroparin a low molecular weight heparin on clinical and angiographic restenosis after coronary balloon angioplasty. The FACT study. Circulation 1997;96:3396–3402.

    Google Scholar 

  11. Reilly CF, Fritze LMS, Rosenberg RD. Heparin inhibition of smooth cell proliferation: A cellular site action. J Cell Biol 1986;129:11–19.

    Google Scholar 

  12. Hanke H, Oberhoff M, Hanke S, et al. Inhibition of cellular proliferation after experimental balloon angioplasty by low molecular weight heparin. Circulation 1992;85:1548–1556.

    Google Scholar 

  13. Popma JJ, Coller BS, Ohman EM, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995;108:486S–501S.

    Google Scholar 

  14. Cohen M, Bigonzi F, Le Louer V, Gosset F, Fromell GJ, Goodman S. One year follow-up of the ESSENCE trial (Enoxaparin versus Heparin in Unstable Angina and Non Q wave Myocardial Infarction). J Am Coll Cardiol 1998; 31(Suppl. A):79A.

    Google Scholar 

  15. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. Circulation 1998;98:294–299.

    Google Scholar 

  16. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular weight heparin and with direct thrombin inhibitor. Circulation 1998;97:251–256.

    Google Scholar 

  17. Knight CJ, Panesar M, Wilson DJ, et al. Increased platelet responsiveness following coronary stenting. Heparin as a possible etiological factor in stent thrombosis. Eur Heart J 1998;19:1239–1248.

    Google Scholar 

  18. Zidar JP. Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting. Am J Cardiol 1998;82:29L–32L.

    Google Scholar 

  19. Deutsch E, Cohen M, Radley DR, Tarazona N, Fromell GJ. Safety and efficacy of percutaneous procedures in patients receiving subcutaneous enoxaparin for unstable angina: Results of the ESSENCE trial. Circulation 1998;98(Suppl.I): I563.

    Google Scholar 

  20. Antman EM, McCabe CH, Premmereur J, et al. Enoxaparin for the acute and chronic management of unstable angina/ non-Q wave myocardial infarction: Results of TIMI 11B. Circulation 1998;98(Suppl. I):I504.

    Google Scholar 

  21. Savage MP, Douglas JS, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med 1997;337:740–777.

    Google Scholar 

  22. Alfonso F, Rodriguez P, Phillips P, et al. Clinical and angiographic implications of coronary stenting in thrombus-containing lesions. J Am Coll Cardiol 1997;29:725–733.

    Google Scholar 

  23. Stone GW, Brodie BR, Griffin JJ, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: In-hospital and 30 day results of the PAMI stent pilot trial. J Am Coll Cardiol 1998;31:23–30.

    Google Scholar 

  24. Kereiakes DJ, Lincoff AM, Miller DP, et al. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent utilization, clinical outcomes and bleeding complications. Circulation 1998;97:857–864.

    Google Scholar 

  25. The EPISTENT investigators. Randomized placebo-controlled and balloon–angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87–92.

    Google Scholar 

  26. Merck research protocol: A randomized, parallel open–label study to investigate the effect on prolongation of bleeding time by low molecular weight heparin vs. unfractionated heparin in tirofiban and aspirin treated patients with unstable angin/non-Q-wave myocardial infarction.

  27. Rhone–Poulenc Rorer research protocol: The safety of enoxaparin therapy in patients undergoing percutaneous coronary intervention receiving concomitant abciximab therapy (NICE-4).

Download references

Author information

Authors and Affiliations

  1. Cardiology Department, Piti;ea-Salp;edtri;eere University Hospital, Paris, France

    Gilles Montalescot

  2. Division of Cardiology, Hahnemann University Hospital, Philadelphia, Pennsylvania, USA

    Marc Cohen

Authors
  1. Gilles Montalescot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montalescot, G., Cohen, M. Low Molecular Weight Heparins in the Cardiac Catheterization Laboratory. J Thromb Thrombolysis 7, 319–323 (1999). https://doi.org/10.1023/A:1008943529597

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008943529597

Keywords

Search

Navigation